Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

621
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
621
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

950
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
950
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

1.1K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Image-quality optimization for late iodine enhancement with photon-counting CT: impact of spectral analysis and reconstruction parameters.

La Radiologia medica·2026
Same author

Diagnostic performance of a single breath-hold lung MRI scan with AI-powered compressed sensing for nodule detection in comparison to photon counting detector-CT.

European radiology·2026
Same author

Time-dependent effects of interleukin-1 blockade by anakinra in myocarditis and inflammatory cardiomyopathy.

European journal of heart failure·2026
Same author

Cardiac Computed Tomography-Guided Procedural Planning for Percutaneous Mitral Paravalvular Leak Closure: Impact on Crossing Time.

The Canadian journal of cardiology·2026
Same author

A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients.

Nature communications·2026
Same author

Independent prognostic value of left ventricular stroke volume index in patients with takotsubo syndrome: insights from the EVOLUTION registry.

Heart (British Cardiac Society)·2026

Related Experiment Video

Updated: Mar 30, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K

2-Deoxy-d-Glucose Ameliorates PKD Progression.

Marco Chiaravalli1, Isaline Rowe1, Valeria Mannella2

  • 1Molecular Basis of Polycystic Kidney Disease Unit.

Journal of the American Society of Nephrology : JASN
|November 5, 2015
PubMed
Summary

Low doses of 2-deoxy-d-glucose (2DG) show promise in treating autosomal dominant polycystic kidney disease (ADPKD). This glucose analog slowed disease progression in mouse models without apparent toxicity, offering a potential new therapy for ADPKD.

Keywords:
ADPKDmetabolismpolycystic kidney disease

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

821
Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K

Related Experiment Videos

Last Updated: Mar 30, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

821
Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium
08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K

Area of Science:

  • Nephrology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease (ESRD) with no current US-approved treatments.
  • Altered glucose metabolism and enhanced glycolysis are characteristic of ADPKD.
  • Glucose analogs have shown therapeutic potential in preclinical PKD models.

Purpose of the Study:

  • To investigate the efficacy of chronic, low-dose 2-deoxy-d-glucose (2DG) treatment in mitigating ADPKD progression.
  • To assess the impact of 2DG on glucose metabolism and cellular markers in ADPKD models.
  • To evaluate the safety profile of long-term 2DG administration.

Main Methods:

  • Utilized inducible Pkd1 inactivation in murine models to establish early and late-onset ADPKD.
  • Administered low-dose 2DG (100 mg/kg, 5 days/week) chronically.
  • Assessed disease progression via kidney volume, cystic index, CD45+ cell infiltration, and histological/behavioral analyses.

Main Results:

  • Cystic kidneys exhibited increased (13)C-glucose uptake and (13)C-lactate conversion, indicative of heightened glycolysis.
  • 2DG treatment normalized renal levels of phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase.
  • 2DG significantly attenuated kidney volume increase, reduced cystic index, and decreased inflammatory cell infiltration.
  • No significant toxicity was observed in brain or heart histology, or in behavioral tests.

Conclusions:

  • 2DG effectively ameliorates ADPKD progression in preclinical models.
  • The therapeutic effects of 2DG are associated with the normalization of key metabolic pathways.
  • Low-dose 2DG demonstrates a favorable safety profile, supporting its potential as an ADPKD therapeutic strategy.